Health
FDA Warns Novo Over Unreported Potential Ozempic Side Effects, Deaths
Packets of Ozempic at the Novo Nordisk production facilities in Hillerod, Denmark.
Photographer: Carsten Snejbjerg/BloombergTakeaways by Bloomberg AISubscribe
Novo Nordisk A/S got a warning letter from the US Food and Drug Administration for not reporting all suspected side effects in patients who took its blockbuster diabetes drug Ozempic.
Among the cases were two deaths and a suicide, the agency said in a March 5 letter and accompanying report. The FDA didn’t stipulate whether the deaths or other side effects were linked to the drug.
